Non-vertebral fracture risk reduction with oral bisphosphonates: challenges with interpreting clinical trial data

References

• Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73–79
   PubMed Web of Science ®Google Scholar
• Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265–71
   PubMed Web of Science ®Google Scholar
• Dargent-Molina P, Favier F, Grandjean H, et al. Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet 1996;348:145–9
   Google Scholar
• Chen YT, Miller PD, Barrett-Connor E, et al. An approach for identifying postmenopausal women age 50–64 years at increased short-term risk for osteoporotic fracture. Osteoporos Int 2007. Epub ahead of print
   Google Scholar
• Delmas PD, Genant HK, Crans GG, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003;33:522–32
   PubMed Web of Science ®Google Scholar
• Johnell O, Oden A, Caulin F, et al. Acute and long-term increase in fracture risk after hospitalization for vertebral fracture. Osteoporos Int 2001;12:207–14
   PubMed Web of Science ®Google Scholar
• Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320–3
   PubMed Web of Science ®Google Scholar
• Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254–9
   Google Scholar
• Melton LJ, III. Vertebral fractures predict subsequent fractures. Osteoporos Int 1999;10:214–21
   PubMed Web of Science ®Google Scholar
• Marcus R, Wong M, Heath H, et al. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 2002;23:16–37
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535–41
   PubMed Web of Science ®Google Scholar
• Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241–9
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077–82
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344–52
   Google Scholar
• Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83–91
   PubMed Web of Science ®Google Scholar
• Siris ES, Brenneman SK, Barrett-Connor E, et al. The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50–99: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int 2006;17: 565–74
   Google Scholar
• van Staa TP, Leufkens HG, Cooper C. Does a fracture at one site predict later fractures at other sites? A British cohort study. Osteoporos Int 2002;13:624–9
   Google Scholar
• Cauley JA, Thompson DE, Ensrud KC, et al. Risk of mortality following clinical fractures. Osteoporos Int 2000;11:556–61
   PubMed Web of Science ®Google Scholar
• Johnell O, Kanis JA, Oden A, et al. Mortality after osteoporotic fractures. Osteoporos Int 2004;15:38–42
   PubMed Web of Science ®Google Scholar
• Chrischilles EA, Butler CD, Davis CS, et al. A model of lifetime osteoporosis impact. Arch Intern Med 1991;151:2026–32
   PubMed Web of Science ®Google Scholar
• Lips P. Invest in your bones: Quality of Life. Why prevent the first fracture? International Osteoporosis Foundation 2003
   Google Scholar
• National Osteoporosis Foundation. Fast facts. 2002. Available from: URL: http://www.nof.org/osteoporosis/diseasefacts.htm
   Google Scholar
• Asthma and Allergy Foundation of America. Asthma Facts and Figures. 2000. Available from: URL: http://www.aafa.org/display.cfm?id=8&sub=42
   Google Scholar
• Cooper C, Campion G, Melton LJ, III. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992;2:285–9
   PubMed Web of Science ®Google Scholar
• Johnell O. The socioeconomic burden of fractures: today and in the 21st century. Am J Med 1997;103:20S–5S
   Google Scholar
• International Osteoporosis Foundation. Osteoporosis in the workplace. 2002. Available from: URL: http://www.iofbonehealth.org/publications/workplace-report.html
   Google Scholar
• Miller PD, Bilezikian JP, Deal C, et al. Clinical use of teriparatide in the real world: initial insights. Endocr Pract 2004;10:139–48
   PubMedGoogle Scholar
• Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688–703
   PubMed Web of Science ®Google Scholar
• Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437–43
   PubMed Web of Science ®Google Scholar
• McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333–40
   PubMed Web of Science ®Google Scholar
• Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999;9:461–8
   PubMed Web of Science ®Google Scholar
• Miller PD. Bisphosphonates: Pharmacology and Use in Osteoporosis. In: Marcus R, Feldman D, Rosen C, Nelson D, eds. Osteoporosis, 3rd edn. Philadelphia: Lippincott, Williams & Wilkins, 2007.
   Google Scholar
• Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006;38:617–27
   PubMed Web of Science ®Google Scholar
• Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999;25:97–106
   PubMed Web of Science ®Google Scholar
• FDA. Guidelines for preclinical and clinical evaluation of agents in the prevention and treatment of postmenopausal osteoporosis. 1994
   Google Scholar
• Delmas PD, Calvo G, Boers M, et al. The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis. Osteoporos Int 2002;13:1–5
   PubMed Web of Science ®Google Scholar
• Brandi ML, Harrington TJ, Barton I, et al. Risedronate reduced the risk of nonvertebral fractures as soon as 6 months in post menopausal osteoporosis. J Bone Miner Res 2002;17(Suppl 1):S270
   Google Scholar
• Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809–22
   PubMed Web of Science ®Google Scholar
• Boonen S, Laan RF, Barton IP, et al. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int 2005;16:1291–8
   PubMed Web of Science ®Google Scholar
• Papapoulos SE, Schimmer RC. Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Ann Rheum Dis 2007;66:853–8
   PubMed Web of Science ®Google Scholar
• Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000;12:1–12
   PubMedGoogle Scholar
• Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.Calcif Tissue Int 2002;71:103–11
   PubMed Web of Science ®Google Scholar
• Cranney A, Wells G, Adachi R. Non-vertebral fracture reduction with high- versus low-dose ibandronate: a meta-analysis of individual patient data. Ann Rheum Dis 2007;66(Suppl. 2):681 (Abstract LB0004)
   Google Scholar
• Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005;20:1315–22
   PubMed Web of Science ®Google Scholar
• Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006;54:1838–46
   PubMed Web of Science ®Google Scholar
• Miller PD, Harris ST, Blumentals WA. Clinical and nonvertebral fracture risk is reduced with the use of ibandronate in women with postmenopausal osteoporosis. J Bone Miner Res 2007;22(Suppl. 1):S451 (Abstract W355)
   Google Scholar